Full-Time
Associate Director
Data Sciences
Posted on 10/31/2025
Certara
1,001-5,000 employees
PBPK/QSP modeling software and services
No salary listed
Hyderabad, Telangana, India
In Person
 Biology & Biotech (2) |
|---|
| , |
- Master’s or PhD in Pharmacology, Pharmaceutical Sciences, or related fields.
- Oversee database development, curation, QC, and deployment to platform (e.g., CODEX); ensure accurate data extraction from literature and plots; validate QC documentation and manage change impact.
- Conduct systematic literature reviews using PICOS, ontologies, and data standards; refine search strategies; apply clinical trial knowledge; perform R-based quality checks and exploratory analyses.
- Lead planning and delivery of database products; manage resources, timelines, and change controls; ensure clear communication with clients and internal teams.
- Mentor teams; drive process improvement, agile practices, and learning initiatives; support hiring and onboarding.
- Align with clients and internal teams on expectations; review project metrics and identify enhancements.
- Stay current with advancements in statistics, R, SLR, and data science; contribute to innovation.
- 10+ years of experience in systematic literature reviews, clinical trial databases, or health economics (6+ years for PhD holders).
- Strong knowledge of clinical research, trial design, PICOS, and pharma data standards.
- Proficiency in R; knowledge of Python and statistical methods is a plus.
- Key Competencies: Collaboration, Communication, Mentorship, Adaptability, Client Focus.
Certara provides biosimulation software and services to help speed up drug discovery, development, and regulatory submissions. Its Simcyp PBPK modeling platform creates virtual patients to run computer-based trials, complemented by quantitative systems pharmacology tools, data repositories, and AI-powered analytics to predict drug behavior and optimize dosing. It differentiates itself by offering an integrated software-plus-consulting approach and expanding capabilities through strategic acquisitions to deliver an end-to-end model-informed drug development solution for industry, academia, and regulators. The goal is to accelerate and de-risk drug development and support more informed regulatory submissions through data-driven, model-based decisions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Princeton, New Jersey
Founded
2008
Simplify's Take
What believers are saying
- NVIDIA collaboration accelerates AI-integrated MID3 platform launch in 2026.
- Arjun Bedi's February 2026 board appointment drives pharma AI transformation adoption.
- Software revenue grew 7% to $49.7M in Q1 2026 despite services decline.
What critics are saying
- Tier 1 pharma headcount cuts suppress Phoenix seat licenses through 2026.
- Pinnacle 21 bookings collapse from 18-month trial start delays until mid-2026.
- Veristat divestiture eliminates $50M high-margin revenue and 220 employees.
What makes Certara unique
- Simcyp Simulator leads PBPK modeling for virtual patient trials and regulatory submissions.
- Certara.AI deploys life science-specific GPTs across proprietary biosimulation data.
- Acquisitions like ChemAxon in 2024 expand QSP and scientific informatics capabilities.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Company News
Cynthia Collins to leave Certara (CERT) board and Audit Committee in May 2026. Filing Impact (Moderate) Filing Sentiment Rhea-AI filing summary. Certara, Inc. reported that board member Cynthia Collins has notified the company of her intention to resign as a Class II director and member of the Audit Committee. Her resignation will be effective on May 14, 2026, the date of Certara's 2026 annual meeting of stockholders. The company states that Ms. Collins' decision to resign is not due to any disagreement with Certara regarding its operations, policies, or practices. This indicates a planned governance change rather than a dispute-driven departure. 8-K event classification. Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Key figures. Resignation effective date: May 14, 2026 Key terms. Audit Committee, Class II director, annual meeting of stockholders 03/31/2026 - 04:30 PM (Exact name of registrant as specified in its charter) (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Securities registered pursuant to Section 12(b) of the Act: On March 27, 2026, Cynthia Collins, a member of the Board of Directors (the "Board") of Certara, Inc. (the "Company") and the Audit Committee of the Board, notified the Company of her intention to resign as a Class II director on the Board, effective as of May 14, 2026, the date of the Company's 2026 annual meeting of stockholders. Ms. Collins advised the Company that her resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Faq. What board change did Certara (CERT) disclose in this Form 8-K? Certara disclosed that Cynthia Collins plans to resign as a Class II director and Audit Committee member. Her resignation is described as voluntary and not due to any disagreement over the company's operations, policies, or practices, suggesting an orderly board transition. When will Cynthia Collins' resignation from Certara's board be effective? Her resignation will be effective May 14, 2026, the date of Certara's 2026 annual meeting of stockholders. Until that date, she continues to serve as a Class II director and member of the Audit Committee under the current board structure. Did Certara (CERT) report any disagreement related to Cynthia Collins' resignation? No. Certara states that Cynthia Collins advised the company her resignation is not the result of any disagreement on operations, policies, or practices. This language is important because it signals there is no reported underlying dispute triggering her departure. What board role did Cynthia Collins hold at Certara before announcing her resignation? Cynthia Collins served as a Class II director on Certara's Board of Directors and was also a member of the Audit Committee. Her planned resignation affects both her general board seat and her oversight responsibilities on that key financial reporting committee. How does this 8-K filing affect Certara's Audit Committee composition? The filing indicates an upcoming vacancy on Certara's Audit Committee when Cynthia Collins' resignation becomes effective on May 14, 2026. The company will need to address replacement or reallocation of committee responsibilities after the 2026 annual meeting of stockholders. Filing exhibits & attachments. 3 documents
Certara closed 2025 meeting revenue guidance and exceeding profitability targets, though software bookings declined in the fourth quarter. Chief Financial Officer John Gallagher said full-year organic software revenue growth reached 7%, within the company's 6% to 8% guidance range, whilst adjusted EBITDA margin hit 32%, the top end of the 30% to 32% range. Fourth-quarter bookings presented a mixed picture. Services bookings rebounded strongly, with December up significantly due to seasonality and budget flush. However, trailing 12-month organic software bookings growth slowed to 4% for the year, with a year-over-year decline in Q4 software bookings driven by reduced Phoenix seat licences amongst Tier 1 pharmaceutical customers experiencing headcount reductions. The company's 2026 outlook projects flat to 4% growth.
Certara has guided 2026 revenue to flat to 4% growth following weaker software bookings, whilst maintaining an EBITDA margin target of 30–32%. The company disclosed that fourth-quarter software bookings fell 6% year-over-year, with organic trailing-twelve-month software bookings growing just 1%. Chief Financial Officer John Gallagher attributed the softness to customer reprioritisation around Phoenix, which reduced seat licences, and lagging study counts affecting Pinnacle 21 due to slower clinical trial starts approximately 18 months earlier. Services showed low-single-digit growth. Under new CEO Jon Resnick, Certara is prioritising biosimulation growth—particularly QSP, Simcyp and PBPK—and AI offerings including Certara IQ and Phoenix Cloud. The company plans to fund research and development whilst pursuing approximately $10 million in cost avoidance and selective acquisitions.
Certara welcomes Arjun Bedi to its Board of Directors. Bedi brings significant expertise in strategy, growth, and execution driving technology-enabled innovation across the healthcare industry RADNOR, PA. - March 12, 2026 - Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announced today the appointment of Arjun Bedi, a life sciences and digital transformation business leader with over 36 years of experience, to its Board of Directors, effective February 2026. Bedi brings deep experience in strategic leadership, operational execution, and digital and AI-driven transformation across the health and life sciences industries. Over his 35 year career at Accenture, he held multiple senior leadership roles and served on the Global Management Committee, accelerating growth in the life sciences and biotech segments serving many of the world's top pharmaceutical and biotech companies, and leading the firm's Global Strategic Client Portfolio. He is also the founder of the annual Health & Life Sciences CEO Forum, now in its 15th year, which convenes CEOs from the top 20 healthcare companies to collaborate on industry strategy and execution best practices. "Arjun is an excellent addition to Certara's board, bringing a powerful combination of technology fluency, growth leadership, and board governance experience," said Jon Resnick, Chief Executive Officer. "His decades of work with many of the world's leading pharmaceutical and biotech organizations will be invaluable in supporting greater industry adoption of biosimulation to help speed innovative new medicines to patients." "Certara is uniquely positioned at the intersection of biosimulation, AI, and drug development. I've seen firsthand how AI-enhanced biosimulation technology can unlock greater certainty in drug development assets while enhancing their commercial performance and patient impact," said Arjun Bedi. "I'm excited to join the board as Certara is poised for accelerated growth." About certara. Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com. Certara contact: Media contact: Certara is transforming drug discovery and development for good. Certara Inc. transform drug development for the benefit of humans. Its commitment is to empower innovators, researchers, and regulatory experts with software and service solutions tailored exactly to meet their needs, fostering success across the entire drug development lifecycle.
Certara announces 2026 Certainty event. Following this year's theme, "Right from the Start", the event will bring together leading experts across the life sciences to discuss the future of AI-enabled technologies from discovery to development RADNOR, PA - March 9, 2026 - Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced Certainty 2026 will be held April 14-15 in Boston, Massachusetts. Now in its third year, the conference brings together a community of leaders across biosimulation, clinical pharmacology, regulatory science and clinical data science to bring greater clarity and confidence to every stage of drug discovery and development. This year's keynote speaker, Dr. David Fajgenbaum, MBA, MSc., co-founder and president of Every Cure and a physician-scientist at the University of Pennsylvania, is pioneering a new model of unlocking life-saving treatments. After discovering the therapy that saved his own life, he's advanced 13 additional treatments and secured more than $100 million to scale globally. At the event, he will talk about the role that quantitative science can play in supporting this mission to bring hope to patients. "As AI and advanced technologies integrate into our workflows, we must meet pace and deliver solutions that embrace the next phase of drug discovery and development. Certainty continues to be an incredible forum for our leaders to join with industry experts to address bottlenecks we face now and solve for the problems of tomorrow," said Jon Resnick, Chief Executive Officer. Certainty 2026 will explore how AI-enabled modeling and simulation is improving decision-making at every stage of R&D. The event will feature in-depth tracks and interactive sessions to further explore specific interests across the entire lifecycle. Tracks include: * AI-Enabled Modeling and Simulation from Strategy to Approval: explore how empirical PK/PD methods like non-compartmental analysis (NCA) and popPK are complementing mechanistic approaches like PBPK and QSP to answer the most daunting challenges in development, from optimal first-in-human dosing to presenting clinical pharmacology evidence effectively in your regulatory submissions. * P21 Live: Digital Data Flow Optimization: follow the flow of data from protocol all the way to submission, from mapping specs and APIs to the progress of its solution for metadata management. This track features several customer presentations from AstraZeneca and Merck, as well as an update on changing regulatory expectations and the tie to standards and submission workflows. Attendees will also engage in rapid-fire roundtables, sharing tactics on automation, analytics, and readiness. * Phoenix User Meeting: explore how empirical pharmacokinetic/pharmacodynamic (PK/PD) methods work alongside in silico approaches and get an interactive look at new features, roadmap, and AI's expanding role in modeling and reporting. Get a sneak peek at the future of Phoenix Cloud for population pharmacokinetic modeling, explore the next era of innovation in PK/PD, and gather with other users to provide feedback and connect with Phoenix product experts. * QSP Summit: learn via featured case studies across disease areas how QSP (Quantitative Systems Pharmacology) is transforming MIDD through computational modeling, AI integration, and mechanistic insights, and take part in forward-looking discussions on regulatory adoption and the future of predictive modeling. Keynote presenter Vaishali Sahasrabudhe, Head of Pharmacometrics and Systems Pharmacology in Translational Clinical Sciences at Pfizer, will speak on Integrating Disease Biology, Pharmacology and Data to Inform Drug Development Decisions. * Discovery: Intelligent Lead Optimization with Chemaxon and D360: discuss the explosion of new modalities and the expanding scope of informatics as AI closes gaps between chemistry, safety, and efficacy, including how predictive modeling is reshaping compound design and enabling a clearer view downstream in drug discovery. The track will explore what it takes for informatics solutions to keep pace with increasing molecular complexity and data diversity. * PBPK (Physiologically-based Pharmacokinetic) Modeling Workshop: see how the Simcyp Simulator informs decisions for first-in-human dosing to formulation, drug-drug interactions, and special population optimization. Expert talks and case studies will offer practical insights to strengthen confidence in model-informed development. Certainty brings together scientists and drug developers from more than 80 biopharmaceutical companies. For more information about Certara's event schedule, including the Certainty APAC and EMEA events, please visit: https://certainty.certara.com/ About certara. Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com. Certara contact: Media contact: AI-Enabled QSP modeling delivers insights faster. Certara IQ is an AI-enabled QSP modeling product that integrates advanced technologies with validated models and workflows to enable more accessible and scalable QSP modeling.